Crofelemer Trial for Canine Diarrhea Achieves Statistical Significance, Nearing Full FDA Approval
JAGX is trading near its 52-week low of $0.24 (5.0% below the low).
Summary
Jaguar Health announced statistically significant topline results from its effectiveness trial of crofelemer (Canalevia-CA1) for chemotherapy-induced diarrhea in dogs. The trial showed treated dogs achieved normal average daily stool after three days, with 83% of owners reporting the treatment was effective. These pivotal results are a critical step towards securing full FDA approval for Canalevia-CA1, which is currently only conditionally approved. This positive product development provides a rare potential catalyst for Jaguar Health, which has recently faced severe financial distress, a Nasdaq delisting threat, and implemented a 1-for-35 reverse stock split to maintain compliance. Investors will now watch for the company's submission for full regulatory approval and further updates on its financial stability.
At the time of this announcement, JAGX was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $0.24 to $13.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Access Newswire.